ArteraAI’s Post

We are thrilled to announce that GAIA's innovative digital therapeutic (DTx) asset, klariva, is being featured in an article on The Pharma Letter! klariva addresses the needs of patients with psoriasis, and we are confident that it has the potential to be a transformative solution for these patients. The article highlights klariva's unique benefits, including: 𝐄𝐦𝐩𝐨𝐰𝐞𝐫𝐦𝐞𝐧𝐭: klariva equips patients with the tools and resources needed to actively manage their condition. 𝐀𝐜𝐜𝐞𝐬𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐲: klariva breaks down barriers to care by providing anonymous and remote access to support, eliminating the stigma and logistical hurdles often associated with traditional therapy. 𝐇𝐨𝐥𝐢𝐬𝐭𝐢𝐜 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡: klariva tackles psoriasis not just as a physical condition, but also addresses the mental and emotional aspects that significantly impact patients' well-being. We're passionate about developing evidence-based and accessible DTx solutions that empower individuals to improve their health. We're thrilled about the potential of klariva to make a positive impact on the lives of psoriasis patients worldwide. Read the full article here: https://lnkd.in/edJgdqjB #DTx #psoriasis #digitalhealth #GAIA #klariva

We published a paper in ACTA Ophthalmologica! https://lnkd.in/d6stEnzp We showed that faricimab is a cost-effective alternative to standard treatment with bevacizumab for patients with nAMD (neovascular age-related macular degeneration). Faricimab's extended treatment interval is particularly beneficial for patients living far from clinics, and if the real-life faricimab injection interval extends beyond 12weeks. Our findings highlight faricimab's potential to free up healthcare staff to treat a larger patient population with existing clinic resources. #umeåuniversity #healtheconomicanalysis #faricimab #bevacizumab #nAMD #swedishmacularegistry #reallifedata

Our Brand Story. Less-invasive solution for #interventionaloncology – learn how we push the boundaries for R2V - Radial to Visceral. ☞ https://bit.ly/3SFr1uE (*The articles in this post are for healthcare professionals in India and Asia Pacific countries excluding Oceanian countries only.)

A 45-year-old man presented with abdominal pain, nausea and diarrhea. He had a history of hyperparathyroidism and a transsphenoidal prolactinoma resection. Which of the following is the most common functional enteropancreatic tumour seen in this condition? Gastrinoma Glucagonoma Insulinoma VIPoma Explanation: It is the most common (50%) functional enteropancreatic tumour seen in MEN1 syndrome. Enteropancreatic tumour (30–70%) : there are following tumours seen  • Gastrinoma (>50%) • Insulinoma (10–30%) • Nonfunctioning and PPoma (20–55%) • Glucagonoma (<3%) • VIPoma (<1%)   Reference: Harrison’s Principles of Internal Medicine, 21e [Internet]. Mhmedical.com. [cited 2023 Jun 14]. Available from: https://lnkd.in/dxp6Hi9f

Which of the following is the best initial management for diabetes in a patient with a BMI of 38? Prescribe oral antidiabetic medication Recommend lifestyle modifications, including diet and exercise Initiate insulin therapy Refer the patient to a bariatric surgery specialist Explanation: The best initial management for diabetes in a patient with a BMI of 38 is to recommend lifestyle modifications, including diet and exercise. This approach is known as the first-line therapy for managing type 2 diabetes. Option 1) Prescribing oral antidiabetic medication may sometimes be necessary, but it is not the best initial management strategy. Lifestyle modifications should be attempted first before considering medication. Option 3) Initiating insulin therapy is not the first-line treatment for type 2 diabetes. Insulin therapy is usually reserved for patients who do not respond to lifestyle modifications and oral medications. Option 4) Referring the patient to a bariatric surgery specialist may be an option for individuals with severe obesity and poorly controlled diabetes. However, it is not the best initial management strategy and should be considered only after lifestyle modifications and medication have been attempted.

A 40-year-old woman presents with severe joint pains for 1 month. She also says her skin feels firm and tight for the past 6 months and progressed rapidly since then. Further history reveals features of mild Raynaud's syndrome for 6 months. On examination, the skin over the fingers, legs, arms, and trunk appear firm and indurated on palpation. Which of the following antibodies will most likely be elevated in this patient? Anti-double-stranded DNA antibody Anti–topoisomerase I antibody Anti-Smith antibody Anticentromere antibody Explanation: Anti–topoisomerase I antibody The given clinical scenario of severe arthralgia and diffuse involvement of the skin with rapid progression, along with a recent history of Raynaud's phenomenon, is suggestive of diffuse systemic sclerosis. Anti–topoisomerase I antibody is most likely to be elevated in this patient. Reasons why this cannot be limited to systemic sclerosis: The onset of Raynaud's syndrome coincides with the onset of skin symptoms, whereas in limited systemic sclerosis, it precedes skin symptoms and has a history of over a decade. Here Raynaud's is less severe, whereas in limited systemic sclerosis, it is more severe. Here, the skin involvement is diffuse, including the trunk, and showed rapid progression, which are features of diffuse systemic sclerosis. Systemic sclerosis is a chronic and progressive disease that involves sclerosis of the skin and the organs. It can be divided into limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSC) depending on the extent of skin involvement. In lcSSc, the skin involvement has a slow progression and is limited to fingers, distal to elbows, and face. This disease has a slow progression. On the contrary, in dcSSc, the skin involvement is early and rapid. It can involve fingers, extremities, face, and trunk. They also have severe joint pains and musculoskeletal involvement. Other options: Options 1 and 3- Anti-double-stranded DNA antibody and anti-Smith antibody are seen in systemic lupus erythematosus. The patients might have a rash over the malar eminences or circular lesions with slightly raised, scaly hyperpigmented erythematous rims. They might also have swelling and tenderness in their hands, wrists, and knees. Option 4- Anti-centromere antibody is seen in limited cutaneous systemic sclerosis. Here, the skin involvement is seen distal to the elbow, in the extremities, and distal to the elbows.

I am proud to share the upcoming priorities for Tajikistan as outlined by our regional office at the World Health Organization. Our focus remains steadfast on improving primary health care (PHC) for all citizens: 🔵 Assessing Bottlenecks in PHC from User Perspective: Understanding the challenges faced by our communities is crucial. By looking at PHC through the lens of those who use it, we can identify and address the specific obstacles that prevent people from accessing the care they need. 🔵 Designing a Family Medicine & Socially-Driven PHC Service Model: We are committed to developing a PHC model that not only addresses medical needs but also considers the social determinants of health and social participation. A holistic approach to family medicine is key to ensuring comprehensive care. 🔵 Designing Model Sites in Three Districts: By creating “Centers of Excellence” in three districts, we aim to set a standard for PHC that can be replicated throughout the country. These model sites will serve as beacons of excellence in healthcare delivery. As a member of the WHO country office in Tajikistan, I am excited to be a part of these transformative initiatives. Together, we can make a significant impact on the health and well-being of our communities. #PublicHealth #PrimaryHealthCare #Tajikistan #WHO Dr Parvina GianMatteo Apuzzo Zulfiya Pirova

New research published from Boston Children's Hospital, Maria Fareri Children's Hospital, a member of the WMCHealth Network, and seizuretracker.com utilizing Patient Reported Outcomes in patients with difficult to treat epilepsy. PROs are always subject to limitations, as is all real world evidence, but so important to have PRO research conducted and published in scientific peer-reviewed journals like https://lnkd.in/gfESAxbu #PROMS #patientoutcomes #patientexperience

𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐔𝐭𝐢𝐥𝐢𝐭𝐲 𝐨𝐟 𝐇𝐨𝐦𝐞 𝐎𝐂𝐓 𝐃𝐚𝐭𝐚 𝐢𝐧 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐨𝐟 𝐍𝐞𝐨𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐀𝐠𝐞 𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐌𝐚𝐜𝐮𝐥𝐚𝐫 𝐃𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 At this year's 47th Macula Society Annual Meeting, Michael Elman, MD presented for the first time, a study looking at clinical decision making on the part of physicians when they have investigational home OCT data and comparing it to the decisions made in the real world without the availability of home OCT data for nAMD patients. His results showed in a significant number of cases, specifically 42.7%, physicians decided not to treat the patient when home OCT data was present. In cases when they did treat patients earlier, it was by more than a week. #digitalhealth #ophthalmology #retina #remotepatientmonitoring #amd

When should a diabetic patient be screened for diabetic retinopathy? Every 2 years for both T1D and T2D patients Every 5 years for T1D patients and every 2 years for T2D patients Every year for T1D patients and every 2 years for T2D patients Every year for both T1D and T2D patients Explanation: Every year for T1D patients and every 2 years for T2D patients Diabetic retinopathy is a complication of diabetes that affects the eyes. Regular screening is crucial to detect and manage this condition. For patients with Type 1 Diabetes (T1D), annual screening is recommended due to the higher risk and early onset of diabetic retinopathy. On the other hand, for patients with Type 2 Diabetes (T2D), screening every 2 years is recommended unless additional risk factors are present, such as a history of retinopathy or poor glycemic control, which may require more frequent screenings. Regular eye examinations are essential to identify any signs of diabetic retinopathy and initiate timely treatment to prevent vision loss.